The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines
- 대한정신약물학회
- Clinical Psychopharmacology and Neuroscience
- Vol.20 No.1
- : SCOPUS, SCIE, KCI등재
- 2022.02
- 37 - 50 (14 pages)
The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) first was published in 2002, and has been revised four times, in 2006, 2012, 2017, and 2021. In this review, we compared recommendations from the recently revised KMAP-DD 2021 to four global clinical practice guidelines (CPGs) for depression published after 2010. The recommendations from the KMAP-DD 2021 were similar to those from other CPGs, although there were some differences. The KMAP-DD 2021 reflected social culture and the healthcare system in Korea and recent evidence about pharmacotherapy for depression, as did other recently published evidence-based guidelines. Despite some intrinsic limitations as an expert consensus-based guideline, the KMAP-DD 2021 can be helpful for Korean psychiatrists making decisions in clinical settings by complementing previously published evidence-based guidelines, especially for some clinical situations lacking evidence from rigorously designed clinical trials.
INTRODUCTION
TREATMENT GUIDELINES FOR COMPARISON
COMPARISONS OF TREATMENT OPTIONS ACROSS TREATMENT GUIDELINES
CONCLUSION
REFERENCES